D
Da Tong Chu
Researcher at Peking Union Medical College
Publications - 10
Citations - 9519
Da Tong Chu is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: Gefitinib & Population. The author has an hindex of 10, co-authored 10 publications receiving 8798 citations. Previous affiliations of Da Tong Chu include AstraZeneca.
Papers
More filters
Journal ArticleDOI
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok,Yi-Long Wu,Sumitra Thongprasert,Chih-Hsin Yang,Da Tong Chu,Nagahiro Saijo,Patrapim Sunpaweravong,Baohui Han,Benjamin Margono,Benjamin Margono,Yukito Ichinose,Yutaka Nishiwaki,Yuichiro Ohe,Jin Ji Yang,Busyamas Chewaskulyong,Haiyi Jiang,Emma Duffield,Claire Watkins,Alison Armour,Masahiro Fukuoka +19 more
TL;DR: Gefit inib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia and the presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib.
Journal ArticleDOI
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka,Yi-Long Wu,Sumitra Thongprasert,Patrapim Sunpaweravong,Swan Swan Leong,Virote Sriuranpong,Tsu Yi Chao,Tsu Yi Chao,Kazuhiko Nakagawa,Da Tong Chu,Nagahiro Saijo,Emma Duffield,Yuri Rukazenkov,Georgina Speake,Haiyi Jiang,Alison Armour,Ka Fai To,James Chih-Hsin Yang,Tony Mok +18 more
TL;DR: EGFR mutations are the strongest predictive biomarker for PFS and tumor response to first-line gefitinib versus carboplatin/paclitaxel and the predictive value of EGFR gene copy number was driven by coexisting EGFR mutation (post hoc analysis).
Journal ArticleDOI
Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
Chee Khoon Lee,Chris Brown,Richard J. Gralla,Vera Hirsh,Sumitra Thongprasert,Chun-Ming Tsai,Eng Huat Tan,James Chung-Man Ho,Da Tong Chu,Adel Zaatar,Jemela Anne Osorio Sanchez,Vu Van Vu,Joseph S. K. Au,Akira Inoue,Siow Ming Lee,Val Gebski,James Chih-Hsin Yang +16 more
TL;DR: EGFR mutation is a predictive biomarker of PFS benefit with EGFR-TKIs treatment in all settings and should be considered as front-line therapy in EGFRmut(+) advanced NSCLC patients, supporting EGFR mutation assessment before initiation of treatment.
Journal ArticleDOI
Biomarker Analyses from a Phase Iii, Randomized, Open-Label, First-Line Study of Gefitinib (G) Versus Carboplatin/Paclitaxel (C/P) in Clinically Selected Patients (Pts) with Advanced Non-Small Cell Lung Cancer (Nsclc) in Asia (Ipass)
Masahiro Fukuoka,Yi-Long Wu,Sumitra Thongprasert,Chih-Hsin Yang,Da Tong Chu,Nagahiro Saijo,Claire Watkins,Emma Duffield,Alison Armour,Tony Mok +9 more
TL;DR: EGFR M status was a strong predictive biomarker for the efficacy of G vs C/P in this clinically selected first-line setting in Asia.
Journal ArticleDOI
Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS).
Sumitra Thongprasert,Emma Duffield,Nagahiro Saijo,Yi-Long Wu,James Chih-Hsin Yang,Da Tong Chu,Meilin Liao,Yuh Min Chen,H.-P. Kuo,Shunichi Negoro,Kwok Chi Lam,Alison Armour,Patrick Magill,Masahiro Fukuoka +13 more
TL;DR: HRQoL and symptom endpoints were consistent with efficacy outcomes in IPASS and favored gefitinib in patients with EGFR mutation-positive tumors and carboplatin/paclitaxel in patients for the overall population and EG FR mutation-negative tumors.